Articles From: Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update to Oplink to be bought by Koch Industries for 14% premium


Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company’s recent corporate developments.
Sign-up for Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the “Top 10 Advanced Therapy Projects to Watch” by Elsevier Business Intelligence for the second consecutive year.
Sign-up for Opexa Therapeutics Selected as One of the “Top 10 Advanced Therapy Projects to Watch” investment picks
Ophthotech Corporation (NASDAQ: OPHT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
Sign-up for Ophthotech Added to NASDAQ Biotechnology Index investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014.
Sign-up for Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014 investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the Credit Suisse 2014 Healthcare Conference investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the Stifel 2014 Healthcare Conference investment picks
Ophthotech Corporation (Nasdaq:OPHT) today provided a business update on the Company and announced financial results for the third quarter ended September 30, 2014.
Sign-up for Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results investment picks
OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age.
Sign-up for OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP) investment picks
OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a multi-institutional, prospective study of the 4Kscore Test in the journal European Urology .
Sign-up for OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore™ Test for High Grade Prostate Cancer in the United States investment picks
OPKO Health, Inc. (NYSE:OPK) , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its third quarter ended September 30, 2014.
Sign-up for OPKO Announces Third Quarter Operating and Financial Results investment picks
OPKO Health, Inc. (NYSE:OPK) and Immuno Technologies, Inc. today announced that the National Institutes of Health (NIH) has awarded a $3 million grant to develop a rapid diagnostic test for Lyme disease.
Sign-up for OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant investment picks
OPKO Health, Inc. (NYSE: OPK) today announced that senior management will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 4:00 PM PT.
Sign-up for OPKO Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 4:20 PM GMT in London.
Sign-up for OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference investment picks
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 25 th Annual Healthcare Conference on Wednesday, December 10, 2014 at 10:20 AM (ET). OPKO’s senior management will provide a review of recent corporate developments.
Sign-up for OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
Shares of Opko Health (OPK) soared 13% in premarket trade Monday, after the biopharmaceutical company announced an agreement with Pfizer Inc. (PFE) to develop its treatment for growth hormone deficiency.
Sign-up for Opko Health's stock soars after Pfizer development agreement investment picks
OPKO Health, Inc. (NYSE: OPK ) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014, before the market opens.
Sign-up for OPKO To Hold Conference Call on November 10, 2014 investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Oplink Communications, Inc. (NASDAQ: OPLK) breached their fiduciary duties in connection with the planned merger of the Company with Koch Optics, Inc., a wholly owned Koch Industries subsidiary.
Sign-up for OPLINK ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Proposed Merger of Oplink Communications, Inc. With Koch Optics, Inc. investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against Oplink Communications, Inc. (NASDAQ:OPLK) (“Oplink Communications” or the “Company”). If you currently own shares of Oplink Communications and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/OPLK or contact Craig J.
Sign-up for OPLINK COMMUNICATIONS (OPLK) ALERT – Andrews & Springer LLC Is Investigating Oplink Communications, Inc. For Potential Securities Fraud and Breach of Fiduciary Duty investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Oplink Communications Inc. (NASDAQ: OPLK) (“Oplink” or the “Company”) relating to the sale of the Company to Koch Optics (“Koch”). On November 19, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Koch will acquire Oplink in a merger via a tender offer.
Sign-up for OPLINK COMMUNICATIONS (OPLK) INVESTIGATION - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Oplink Communications, Inc. investment picks
2014/11/25
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Oplink Communications, Inc. (“Oplink”) (NasdaqGS: OPLK) concerning the buyout by Koch Industries, Inc. Under the terms of the definitive agreement, valued at approximately $445 million, Oplink shareholders will only receive $24.25 in cash per Oplink share owned.
Sign-up for OPLINK COMMUNICATIONS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Buyout by Koch Industries investment picks
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Oplink Communications, Inc. NEW YORK , Nov.
Sign-up for OPLINK COMMUNICATIONS, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Oplink Communications, Inc. Over the Proposed Sale of the Company to Koch Industries, Inc. - OPLK investment picks
2014/11/19
WILMINGTON, Del.
Sign-up for OPLINK COMMUNICATIONS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
FREMONT, Calif., Oct.
Sign-up for Oplink Reports First Quarter of Fiscal Year 2015 Financial Results investment picks
Oplink Shareholders for Change (“OSC”), a group led by Engaged Capital, LLC (“Engaged Capital”) and Voce Capital Management LLC (“Voce Capital”), released today a letter to shareholders of Oplink Communications Inc. (“Oplink” or the “Company”) (NASDAQ:OPLK) highlighting the Board’s continued abandonment of their responsibility to call the Annual Meeting of shareholders.
Sign-up for Oplink Shareholders for Change (OSC) Release Letter to Fellow Shareholders investment picks
Oplink to be managed by Molex Transaction to significantly expand Molex's fiber optic capabilities FREMONT, Calif.
Sign-up for Oplink to be Acquired by Koch Industries for $24.25 Per Share in Cash investment picks
Oplink Communications (OPLK) has agreed to be acquired by privately-held Koch Industries for about $445 million in cash.
Sign-up for Oplink to be bought by Koch Industries for 14% premium investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update to Oplink to be bought by Koch Industries for 14% premium
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent